Improved patient care
High or low blood glucose increases the risk of death or complications. Normalizing glucose improves outcomes, if harmful extremes can be avoided.
Reduced ICU costs
Reducing length of stay and complications has a significant and beneficial impact on the costs of the intensive care units (ICU).
An unsolved problem
Over $500 million has been spent trying to make continuous glucose monitoring possible in the ICU, but the problem remains unsolved.
By accessing through an indwelling arterial catheter without disrupting that catheter's current use, the GlucoSet sensor requires no new catheters and displaces no other equipment.
The arterial access makes the GlucoSet sensor less susceptible to coagulation and sensitivity to intravenous nutrition. Unlike competing solutions, the sensor also tolerates patient movement very well.
Easy to adopt
The product can be set up by nurses without advance planning, available in minutes after the decision has been made to monitor glucose.
With a sensor cross sectional area under 5% of the smallest competing product, GlucoSet is the first sensor able to access through arterial catheters without risk.
With a simple system design that relies on few and commercially available components, the GlucoSet system is optimized for low-cost mass production.
Strong IPR protection
GlucoSet's technology platform and the manufacturing process is covered by granted patents, and the company is actively expanding the patent portfolio.
The GlucoSet core team has both expert researchers and the necessary understanding of the medical field. Through seasoned technical advisors, the team has access to years of know-how and knowledge.
The board members contribute to the company with years of experience from medtech entrepreneurship and business development.
The advisory board consists of international experts within their fields, either as clinical experts or in medtech business development.